Forte Biosciences is readying its upcoming financial earnings report as the market closely monitors its pending $2.2 billion acquisition by argenx. The corporate developments arrive as investors weigh the strategic implications of the impending transaction on Forte Biosciences' ongoing financial reporting and clinical pipeline.
Financial analysts and stakeholders await further details regarding the timing of the earnings release and the finalization stages of the argenx agreement. Further announcements from both companies are expected as the transaction moves toward its conclusion.
